Krystal Biotech shares are trading higher after the company last week received FDA approval for VYJUVEK.
Portfolio Pulse from Benzinga Newsdesk
Krystal Biotech shares are trading higher after the company received FDA approval for VYJUVEK last week.
May 22, 2023 | 2:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Krystal Biotech's stock price is trading higher after receiving FDA approval for VYJUVEK.
The FDA approval for VYJUVEK is a significant milestone for Krystal Biotech, as it validates the company's product and opens up a new revenue stream. This positive news is driving the stock price higher in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100